hVIVO Overview
- Year Founded
-
1988
- Status
-
Acquired/Merged
- Employees
-
174
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$16.8M
- Investors
-
1
hVIVO General Information
Description
Developer of antiviral drugs and vaccines designed for respiratory and enteric diseases. The company offers testing of infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials, enabling pharmaceutical and biotech sponsors to conduct human challenge trials with robust safety oversight, streamlined regulatory compliance, and comprehensive end-to-end operational and scientific support.
Contact Information
Website
www.hvivo.com(Operating Subsidiary)
Corporate Office
- 40 Bank Street, Floor 24
- London E14 5NR
- England, United Kingdom
Corporate Office
- 40 Bank Street, Floor 24
- London E14 5NR
- England, United Kingdom
hVIVO Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 09-Dec-2019 | $16.8M | Completed | Generating Revenue | ||
| 7. PIPE | 26-Nov-2015 | Completed | Generating Revenue | |||
| 6. PIPE | 14-Aug-2014 | Completed | Generating Revenue | |||
| 5. IPO | 03-May-2012 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 16-May-2011 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series B) | 15-Oct-2009 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series A) | 24-Aug-2006 | $1.89M | $1.89M | Completed | Generating Revenue | |
| 1. University Spin-Out | 01-Dec-1988 | Completed | Startup |
hVIVO Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary 1 | ||||||||
| Series B | ||||||||
| Ordinary | 145,658 | $0.001643 | $2.93 | $2.93 | 1x | $2.93 | 4.72% |
hVIVO Patents
hVIVO Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202114656-D0 | Biomarker | Inactive | 13-Oct-2021 | ||
| GB-202114655-D0 | Biomarkers | Inactive | 13-Oct-2021 | ||
| GB-201805472-D0 | Biomarkers and methods for classifying subjects following viral exposure | Inactive | 03-Apr-2018 | ||
| JP-2021507921-A | Methods and compounds for the treatment or prevention of hypercytokine storms and severe influenza | Active | 22-Dec-2017 | ||
| WO-2019122909-A1 | Methods and compounds for the treatment or prevention of hypercytokinemia and severe influenza | Inactive | 22-Dec-2017 | A61K31/437 |
hVIVO Signals
hVIVO Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aquarius Equity Partners | Venture Capital | Minority | ||
| Calculus Capital | PE/Buyout | Minority | ||
| IP Group | Venture Capital | Minority | ||
| Northern Initiatives | Lender/Debt Provider | Minority | ||
| Queen Mary University of London Endowment | Limited Partner | Minority |
hVIVO Investments & Acquisitions (8)
hVIVO’s most recent deal was a Merger/Acquisition with CRS Clinical Research Services for . The deal was made on 27-Aug-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CRS Clinical Research Services | 27-Aug-2026 | Merger/Acquisition | BPO/Outsource Services | ||
| Cryo-Store | 27-Feb-2025 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| CRS Clinical Research Services (Two Clinical Research Units) | 29-Jan-2025 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| CHIMagents | 15-Jul-2020 | Merger/Acquisition | Other Healthcare Services | ||
| Venn Life Sciences | 28-Jun-2019 | Merger/Acquisition | Other Healthcare Services |
hVIVO Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Venn Life Sciences | Breda, Netherlands | 2007 | |
| Cryo Store | Joure, Netherlands | 1999 |
hVIVO FAQs
-
When was hVIVO founded?
hVIVO was founded in 1988.
-
Where is hVIVO headquartered?
hVIVO is headquartered in London, United Kingdom.
-
What is the size of hVIVO?
hVIVO has 174 total employees.
-
What industry is hVIVO in?
hVIVO’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is hVIVO a private or public company?
hVIVO is a Private company.
-
What is the current valuation of hVIVO?
The current valuation of hVIVO is .
-
What is hVIVO’s current revenue?
The current revenue for hVIVO is .
-
How much funding has hVIVO raised over time?
hVIVO has raised $119M.
-
Who are hVIVO’s investors?
Aquarius Equity Partners, Calculus Capital, IP Group, Northern Initiatives, and Queen Mary University of London Endowment have invested in hVIVO.
-
When was hVIVO acquired?
hVIVO was acquired on 09-Dec-2019.
-
Who acquired hVIVO?
hVIVO was acquired by Venn Life Sciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process